Pakistan has recorded a significant 34 percent increase in the export of pharmaceuticals and medical devices, a development that experts describe as a positive outcome of regulatory reforms and improved governance in the health sector.
According to data released by the Drug Regulatory Authority of Pakistan, the rise in exports has been driven by streamlined drug registration processes, regulatory reforms, digitalization, and enhanced transparency within the system.
DRAP stated that major steps have been taken to facilitate exports by drastically reducing certification and registration timelines. The export registration period for pharmaceutical products has been shortened from 60 days to just 10 days, while medical device registrations are now being completed within 20 days.
The authority further noted that several export certificates, which previously took up to 30 days to be issued, are now being processed within just five days, providing timely relief to exporters.
Currently, nearly 70 percent of DRAP’s regulatory operations have been digitalized, with full digitalization targeted by March. The introduction of online medical device registration and the e-office system has significantly reduced errors and delays in regulatory processing.
DRAP officials explained that these improvements have helped ensure the timely availability of advanced and life-saving medical technologies for patients. In addition, the approval timeline for new therapies and cancer-related products has been reduced to three months.
To further strengthen quality assurance, a nationwide quality control laboratory network is being developed, while provincial drug testing laboratories are also being upgraded to meet international standards.
Officials emphasized that these reforms will not only boost Pakistan’s pharmaceutical and medical device exports but will also help ensure the availability of safe, effective, and high-quality medicines for the public.
